Haisco Pharmaceutical
As of the edition of 20 October 2026, Haisco Pharmaceutical runs 26 drugs, 1 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 22 |
| Status not established | 3 |
| Total | 26 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Cipepofol | Ends 2031 (exclusivity) | 0 |
A route B row is one company at one target.
Where its trials are
- Lungs and airways: 10 trials led
- Hormones: 7 trials led
- Nutrition and metabolism: 7 trials led